Search Results
Feb 09, 2026, 03:10 ET Diamyd Medical receives Notice of Allowance for key retogatein US patent
antigen-specific immune tolerance to GAD65 and preserve endogenous insulin production in individuals with type 1 diabetes who carry the HLA DR3-DQ2 gene. Retogatein has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically
More news about: Diamyd Medical AB
Feb 05, 2026, 20:00 ET Sky Labs signe un accord de distribution exclusive avec Otsuka Pharmaceutical pour « CART BP pro » au Japon
conventionnels utilisent un brassard gonflable pour exercer une pression et interrompre temporairement la circulation sanguine, ce qui provoque souvent une gêne, des douleurs et des perturbations du sommeil lors des mesures nocturnes.À l'inverse, CART BP pro repose sur la technologie de photopléthysmographie
More news about: Sky Labs
Feb 05, 2026, 12:35 ET Zenocutuzumab‑zbco Receives FDA Orphan Drug Designation for Treatment of Cholangiocarcinoma
cholangiocarcinoma harboring NRG1 gene fusion."Patients with cholangiocarcinoma face a particularly aggressive cancer with poor prognosis and limited treatment options. Receiving Orphan Drug Designation for zenocutuzumab in patients with CCA harboring the NRG1 gene fusion is a significant regulatory
More news about: Partner Therapeutics, Inc.
Feb 05, 2026, 09:35 ET $207B Market Shift: The Race for Fast Track Approval in Oncology
Application for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval marks the second indication in China for the next-generation tyrosine kinase inhibitor, which demonstrated robust and durable efficacy
More news about: USA News Group
Feb 05, 2026, 08:41 ET VERTESS Closes Four Healthcare Transactions in Strong Start to 2026
https://www.ccgro.com), a lower middle-market independent sponsor based in Arizona. Managing Director Gene Quigley guided this transaction to its successful conclusion. He stated, "I'm extremely pleased for both our client, Robert DeLair, and the buyer as
More news about: Vertess Healthcare Advisors, LLC
Feb 05, 2026, 08:30 ET Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
President and Chief Executive Officer. "DMD is one of the most devastating childhood diseases. Families urgently need better options beyond steroids and gene-targeted approaches. While oncology remains our core focus, this milestone highlights (Z)-endoxifen's potential as a platform therapy in both cancer
More news about: Atossa Therapeutics Inc
Feb 05, 2026, 08:00 ET Providence Therapeutics Announces Appointment of Leah Goodman to the Board of Directors
policy shaping, market access and regulatory affairs across a breadth of therapeutic areas including oncology and immunotherapies, as well as cell and gene therapy advanced GMP manufacturing. Leah holds a Bachelor of Science and a Masters Degree in Commerce both from the University of NSW. She is
More news about: Providence Therapeutics Holdings Inc
Feb 05, 2026, 07:00 ET Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
approved to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey,
More news about: Insmed Incorporated
Feb 05, 2026, 04:00 ET BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration
brings 30+ years' experience in biomanufacturing.Lucy Foley, CEO, eXmoor- Lucy is CEO of eXmoor Pharma, a UK-based cell and gene therapy CDMO. She is Vice Chair of the BIA Manufacturing Advisory Committee and a founding member of the Advanced Therapy Medicinal Manufacturing Community.Lynn
More news about: BioPhorum
Feb 05, 2026, 03:47 ET Proteomics Market Growing at an 11.87% CAGR to 2031 as Precision Medicine & Drug Discovery Adoption Rise, Says a 2026 Mordor Intelligence Report
diagnostics. Gene Therapy Market: The gene therapy market is estimated to be valued at USD 10.04 billion in 2026 and is projected to reach USD 25.89 billion by 2031, registering
More news about: Mordor Intelligence Private Limited
Feb 04, 2026, 17:31 ET Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
immuno-oncology approaches.Oncorine: Shanghai Sunway BiotechOncorine, also known as H101, is a genetically engineered adenovirus with an E1B gene deletion developed by Shanghai Sunway Biotech in China. It is administered alongside chemotherapy to treat nasopharyngeal carcinoma and head and neck
More news about: DelveInsight Business Research, LLP
Feb 04, 2026, 16:55 ET Federal Funding Bill Commits $3 Million to Versiti Blood Research Institute Expansion
bedsides across America—from innovative hemorrhage treatments that protect military personnel to breakthrough personalized cancer therapies and ongoing gene therapy trials offering new hope to patients with hemophilia A.The 79,000-square-foot expansion will house cutting-edge laboratories where scientists
More news about: Versiti, Inc.
Feb 04, 2026, 12:00 ET New Study: Payer Blocking Strategies Delay Care for One in Five Migraine Patients
versions exist.The urgency of this issue is underscored by a recent position statement from the American Headache Society, which supports calcitonin gene-related peptide (CGRP) targeting therapies as first-line options for migraine prevention. Patients should not have to be failed by preventive treatments
More news about: The Headache & Migraine Policy Forum
Feb 04, 2026, 09:05 ET Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program
Dystrophy (DMD)DMD is a rare and incurable pediatric disease affecting approximately 1 in 3,500-5,000 male births caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle function, resulting in the inability
More news about: Cumberland Pharmaceuticals Inc.
Feb 04, 2026, 09:00 ET Paving a path for future veterinary medical professionals
education for the veterinary community. And while this is core to our mission, so is nurturing the next generation of animal healthcare professionals," said Gene O'Neill, NAVC CEO. "Working with the Believe and Belong in Veterinary Medicine program gives NAVC the opportunity to interact with aspiring veterinary
More news about: North American Veterinary Community (NAVC)
Feb 04, 2026, 09:00 ET PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
reproducible results across thousands of archival tissues. Xenium's high-throughput workflow, combined with the ability to generate custom-designed gene panels in collaboration with 10x teams, enabled the consortium to configure assays aligned with the molecular features most relevant to specific cancers."Turning
More news about: 10x Genomics, Inc.
Feb 04, 2026, 08:40 ET Spring Tick Season Increases Risk of Bovine Anaplasmosis, Prompting Call for Early Vaccination
delivering high-quality vaccines that meet the evolving needs of veterinarians and livestock producers worldwide.Media Contact:Gene LutherUniversity Products(225) [email protected]
More news about: University Products
Feb 04, 2026, 08:30 ET Enhancing Monoclonality Assurance in Cell Line Development: Seeing More at Day-0, Upcoming Webinar Hosted by Xtalks
-- Assuring that a stable cell line originates from a single progenitor cell is a fundamental component of the development of protein, cellular and gene therapies. However, monoclonality assurance is often a rate-limiting step in cell line development, leading to project delays and increased risk.
More news about: Xtalks
Feb 04, 2026, 06:30 ET Azenta Reports First Quarter Results for Fiscal 2026, Ended December 31, 2025
Organic revenue, which excludes the impact from foreign exchange, was flat year over year, primarily driven by growth in Next Generation Sequencing and Gene Synthesis, largely offset by a year-over-year decline in Sanger Sequencing.Summary of GAAP Earnings Results - Continuing
More news about: Azenta
Feb 03, 2026, 09:00 ET Slingshot Biosciences Announces Rapid Expansion into the United Kingdom and European Union Markets
Life sciences innovator and leader in precision-engineered synthetic cell mimic technology expands its UK/EU operations to accelerate cell and gene therapy and pharmaceutical developmentEMERYVILLE, Calif., Feb. 3, 2026
More news about: Slingshot Biosciences
Feb 03, 2026, 09:00 ET Slingshot Biosciences Announces Rapid Expansion into the United Kingdom and European Union Markets
Life sciences innovator and leader in precision-engineered synthetic cell mimic technology expands its UK/EU operations to accelerate cell and gene therapy and pharmaceutical developmentEMERYVILLE, Calif., Feb. 3, 2026
More news about: Slingshot Biosciences
Feb 03, 2026, 08:00 ET ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy
for in vivo delivery of any biologic therapeutic using oral small molecules. This transformative riboswitch gene regulation technology allows precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on the regulated in vivo
More news about: ZipBio
Feb 03, 2026, 08:00 ET Empire Today Names Horizon Next Media AOR for Full Funnel Strategy to Build Preference and Drive New Customer Acquisition
execution—they wanted clarity, accountability, and a path to sustained growth as demand for home improvement accelerates among Empire's target consumer," said Gene Turner, President, Global Chief Client Officer, Horizon. "By combining cost analysis, advanced measurement, and hands-on optimization, we are making
More news about: Horizon Media
Feb 02, 2026, 16:30 ET PROSPERITY BANCSHARES, INC.® COMPLETES MERGER WITH SOUTHWEST BANCSHARES, INC.
Prosperity Bank's operations. Additional members of Texas Partners management will maintain leadership roles in the combined organization. In addition, Gene Dawson, Jr., Interim Chairman, President and Chief Executive Officer of Southwest, has joined the Board of Directors of Prosperity Bank.Texas
More news about: Prosperity Bancshares, Inc.
Feb 02, 2026, 12:33 ET 20 Years of Prizes: Vilcek Foundation Honors 14 New Immigrants and Visionaries
novel drug treatments for diseases including cancer. Born in Austria, Luger immigrated to the United States to study nucleosomes and their impact on gene expression. She is an investigator at the Howard Hughes Medical Institute and a distinguished professor and Jennie Smoley Caruthers Endowed Chair of
More news about: The Vilcek Foundation